AstraZeneca, in the presence of His Royal Highness The Prince of Wales, formally unveiled The Discovery Centre (DISC) in Cambridge, UK – a state-of-the-art research and development (R&D) facility designed to the world’s highest environmental standards and accommodating over 2,200 research scientists.

The new £1bn facility will include the most advanced robotics, high-throughput screening and AI-driven technology. It will support AstraZeneca’s focus on specialised and precision medicines and foster the discovery and development of next generation therapeutics, including nucleotide-based, gene-editing and cell therapies.

Pascal Soriot, Chief Executive Officer, AstraZeneca, said: “Our ambition today is to not only unveil a building, but to also drive the next wave of scientific innovation. Our new Discovery Centre in Cambridge raises the bar for sustainable R&D and global collaboration across our industry. It will allow us to break new boundaries in the understanding of disease biology, bring life-changing medicines to patients and power the next stage of our company’s growth.”

The DISC will add to AstraZeneca’s R&D presence in more than 40 countries across the globe, including its other strategic research centres in Sweden and the US, and development facilities in China and Japan.

The Company invests more than $7bn in R&D globally each year, a large part of which takes place in the UK. The Centre will help further nurture partnerships, develop the next generation of science leaders and accelerate AstraZeneca’s industry-leading levels of productivity.

Located within the Cambridge Biomedical Campus the physical proximity of the building’s 19,000m laboratories to leading hospitals, the University of Cambridge, other research institutions and a number of biotech companies will promote a culture of open partnership and innovation in its inviting open spaces. The Company has over 200 active collaborations in the region and more than 2,000 around the world across academia, biotech and industry.